In vitro effectiveness of CB469, a MET tyrosine kinase inhibitor in MET-activated cancer cells
Authors:
Open Access
- 1 November 2024
- journal article
- research article
- Published by Springer Nature in Applied Biological Chemistry
- Vol. 67 (1) , 1-9
Abstract
Gene alterations in receptor tyrosine kinases can result in oncogenic driver mutation in non-small cell lung cancer (NSCLC) including in genes like EGFR, ALK and MET. MET amplifications and MET exon14 skipping are the primary genetic changes in MET-altered cancers. Acquired MET mutations mediate resistance to clinical MET-targeted therapy in NSCLC. MET kinase domain secondary mutations (D1228X, Y1230X) confer resistance to type I MET tyrosine kinase inhibitors (TKIs) in METexon14-altered or MET amplified NSCLC. Here, we investigated the preclinical activity of a novel MET inhibitor, CB469, with cell growth, signaling pathway and colony formation. We confirmed that CB469 inhibited the activity of MET wild and secondary mutant kinases, D1228N and Y1230H, as a type II inhibitor. CB469 also inhibited cell growth and cell signaling proteins in MET-activated or MET exon14 skipping-mutated cancer cell lines and NIH/3T3 cells expressing an engineered MET mutant. CB469 exhibited the inhibitory efficacy comparable with that of capmatinib in migration of EBC-1(METwt) and Hs746T(METΔex14) cells. Finally, CB469 showed selective and potent inhibition in MET-activated cancer cells among MET TKIs leading to enhanced selectivity for MET-mutant versus wild type MET with inhibition of cell growth in NIH/3T3 cells expressing an engineered MET mutant variant.Keywords
Funding Information
- Institute of CHA Advanced Research (CARI-RD-034)
This publication has 21 references indexed in Scilit:
- Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitorsEuropean Journal of Cancer, 2022
- Type II c-Met inhibitors: molecular insight into crucial interactions for effective inhibitionMolecular Diversity, 2021
- Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung CancerNew England Journal of Medicine, 2020
- AXL/MET dual inhibitor, CB469, has activity in non-small cell lung cancer with acquired resistance to EGFR TKI with AXL or MET activationLung Cancer, 2020
- Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLCClinical Cancer Research, 2020
- Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping MutationsNew England Journal of Medicine, 2020
- MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung CancerClinical Cancer Research, 2020
- Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In VitroJournal of Thoracic Oncology, 2019
- Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR -Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to CrizotinibJournal of Thoracic Oncology, 2018
- Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 SkippingJournal of Thoracic Oncology, 2017